病毒载体介导的疗法是否与异常的糖基化相容?
I J J Muffels1, R Budhraja2,3, S Radenkovic4
1Department of Genetic and Genomic Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison avenue, New York, NY 10029, USA.
Molecular therapy. Methods & clinical development
|August 14, 2025
概括
改变的细胞表面糖会影响腺相关病毒 (AAV) 基因疗法. 这项研究显示,在先天性糖化 (CDG) 疾病中,AAV结合甘氨酸和核心受体减少,因此需要针对神经疾病进行优化AAV载体选择.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 神经科学是一个神经科学.
背景情况:
- 腺相关病毒 (AAVs) 是关键的基因疗法载体,转导效率取决于细胞表面的糖干相互作用.
- 在神经发育和神经退行性疾病中常见的蛋白质糖化中断可能会阻碍AAV基因传递.
- 了解糖化对AAV结合的影响对于改善治疗策略至关重要.
研究的目的:
- 为了研究血糖化 (CDG) 的先天性障碍中改变的糖化如何影响AAV结合的甘氨酸物种和核心受体的丰富性.
- 评估AAV载体选择在CDG和相关神经疾病中的影响.
主要方法:
- 利用了来自ALG13-, PMM2-和PGM1-CDG.个体的人类皮质大脑器官和心肌细胞的糖蛋白组学数据.
- 在蛋白质组学数据集中量化了AAV结合型甘氨酸基因和共受体 (例如PDGFRβ) 的丰度.
主要成果:
- 在所有研究的CDG亚型中观察到AAV结合型甘氨酸物种的显著下调.
- PGM1-CDG显示了对AAV5,AAV8和AAV9结合至关重要的甘氨酸基因的显著减少.
- 在ALG13-CDG中,核心受体PDGFRβ的丰度显著下降.
结论:
- 在CDG模型中的异常蛋白质糖化导致AAV结合甘氨酸和核心受体的减少.
- 这凸显了需要仔细选择针对CDG和神经退行性疾病 (如帕金森氏症和阿尔茨海默氏症) 患者的特定糖化特征的AAV载体的必要性.
更多相关视频
09:20Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
Published on: October 18, 2022
4.7K
03:52Author Spotlight: Efficient Adeno-Associated Virus Isolation for Pre-Clinical Applications
Published on: February 9, 2024
2.9K
相关概念视频
01:29Microorganisms in Medicine and Therapeutics
330
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
330
00:59Gene Therapy
25.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.9K